Burnham Institute for Medical Research (Burnham) is pleased to announce that five of its postdoctoral fellows will present seven papers on their data at the American Association for Cancer Research (AACR) 100th Annual Meeting 2009. In addition, John C. Reed, MD, PhD, Burnham President and CEO, Professor and Donald Bren Presidential Chair, will chair a panel on Apoptosis-based Strategies for Cancer Therapy, where he will also present his own research.
This year’s meeting, being held in Denver from April 18 to 22, will highlight the best cancer science and medicine from institutions all over the world. In addition to Dr. Reed, Burnham researchers presenting at the AACR meeting include:
- Lilach Agemy, PhD, who will present Nanoparticle-induced Vascular Blockade in Prostate Cancer.
- Jason Garrison, PhD, who will discuss ARTS and Siah Collaborate in a Novel Pathway for XIAP Degradation
- Shi Ranxin, PhD, who will present two papers: Cyclosporin A Sensitizes Cancer Cells to Death Receptor-Mediated Apoptosis and Chemical Biology Strategy Reveals Pathway-Selective Inhibitor of NFκB Activation Induced by Protein Kinase C and Antigen Receptors.
- Changming Fang, PhD, who will also present two papers: Ileal Bile Acid Binding Protein Mediates the Chemopreventative Effect of Ursodeoxycholic Acid by Activating Nuclear Receptor FXRα in Colorectal Cancer and Genetic Deletion of FXRα Promotes Colon Tumorigenesis in ApcMin/+ Mice
- Adam Richardson, PhD, will present The Role of Pentose Phosphate Pathway in the Warburg Effect.